Supplemental material
Expert Review of Vaccines
Volume 23, 2024 - Issue 1
Original Research
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
Masayoshi Shinjoha Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
https://orcid.org/0000-0002-6291-7186View further author information
https://orcid.org/0000-0002-6291-7186View further author information, Kanae Togob Health and Value, Pfizer Japan Inc, Tokyo, Japanhttps://orcid.org/0000-0003-3964-4009View further author information
https://orcid.org/0000-0003-3964-4009View further author information, Tomoyuki Hayamizub Health and Value, Pfizer Japan Inc, Tokyo, Japanhttps://orcid.org/0009-0002-2989-4303View further author information
https://orcid.org/0009-0002-2989-4303View further author information, Naohiro Yonemotob Health and Value, Pfizer Japan Inc, Tokyo, Japanhttps://orcid.org/0000-0003-3637-2095View further author information
https://orcid.org/0000-0003-3637-2095View further author information, , Johnna Perdrizetd Global Value and Evidence, Pfizer Canada, Montreal, QC, Canadahttps://orcid.org/0000-0002-4260-7607View further author information
https://orcid.org/0000-0002-4260-7607View further author information & Kazumasa Kameib Health and Value, Pfizer Japan Inc, Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-7220-5142View further author information
https://orcid.org/0000-0001-7220-5142View further author information show all